UAB30, a Novel RXR Agonist, Decreases Tumorigenesis and Leptomeningeal Disease in Group 3 Medulloblastoma Patient-Derived Xenografts

BACKGROUND: Group 3 tumors account for approximately 25–30% of medulloblastomas and have the worst prognosis. UAB30 is a novel synthetic rexinoid shown to have limited toxicities in humans and significant efficacy in the pediatric neuroectodermal tumor, neuroblastoma. We hypothesized that treatment...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Neurooncol
Egile Nagusiak: Garner, Evan F., Stafman, Laura L., Williams, Adele P., Aye, Jamie M., Goolsby, Caroline, Atigadda, Venkatram R., Moore, Blake P., Nan, Li, Stewart, Jerry E., Hjelmeland, Anita B., Friedman, Gregory K., Beierle, Elizabeth A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6239946/
https://ncbi.nlm.nih.gov/pubmed/30132166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2950-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak